Pharvaris N.V. reported full-year 2025 results, posting a net loss of €175.7 million and a basic loss per share from continuing operations of €2.97, widening from the prior year. Alongside these ...
Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...
In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Top Stocks Fund Managers Are Loading Up On in 2026. On March 30, 2026, Merck & Co., Inc. (NYSE:MRK) announced positive Phase 3 CORALreef AddOn trial ...
A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...
With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its ...
Hello, and welcome to this market update with the Swedish Diabetes Research Company, Diamyd Medical. On Friday evening, the company announced negative interim results from its Phase III study. We will ...
Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) ...
The dual announcement triggered an immediate and powerful response from investors. Phase 3 of the TAUX presale, which opened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results